Shah Wealth Advisors, LLC’s CRISPR Therapeutics CRSP Stock Holding History

Shah Wealth Advisors, LLC’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.77M	Buy	+69,060	New	+$3.64M	0.87%	23

Other funds holding CRSP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Shah Wealth Advisors, LLC's CRSP Position: Q2 2026 in Review

Shah Wealth Advisors, LLC opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 69,060 shares worth $3.77M. The stake represents 0.87% of the portfolio and ranks #23 among its holdings.

266 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Shah Wealth Advisors, LLC held 69,060 shares of CRISPR Therapeutics worth $3.77M as of Q2 2026.
CRISPR Therapeutics was a new Shah Wealth Advisors, LLC position in Q2 2026.
CRISPR Therapeutics made up 0.87% of Shah Wealth Advisors, LLC's portfolio in Q2 2026, its #23 holding.
266 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Shah Wealth Advisors, LLC's 13F filing for Q2 2026, filed 7 Aug 2026.